Table 1.
Cancer cell toxicity of NHI class LDH-A inhibitors [a]
| Cancer cell line |
Tissue of origin |
IC50 values
(µM) |
||
|---|---|---|---|---|
| NHI-1 | NHI-2 | NHI-Glc-2 | ||
| HeLa | Cervix | 43.8 ± 4.6 [16b] | 33.4 ± 1.0[16b] | 7.2 ± 0.2 |
| A549 | Lung | 131.0 ± 17.6 | 44.1 ± 6.2 | 17.2 ± 3.0 |
| H1299 | Lung | 141.0 ± 11.1 | 61.1 ± 11.8 | 18.0 ± 1.5 |
| H226 | Lung | 120.7 ± 7.8 | 43.4 ± 5.3 | 16.8 ± 2.8 |
| MCF-7 | Breast | 124.3 ± 7.1 | 64.9 ± 13.1 | 16.7 ± 1.1 |
| BT549 | Breast | 110.1 ± 9.5 | 34.5 ± 10.0 | 12.7 ± 0.4 |
| IGROV-1 | Ovary | 123.3 ± 6.8 | 57.4 ± 7.3 | 15.5 ± 3.0 |
| WT-MEF | Normal fibroblast | 245.0 ± 13.0 | 80.5 ± 8.2 | 32.2 ± 0.2 |
[a]
All cells were seeded at 5000 cells/well in plates in which vehicle or compound in DMSO was pre-dispensed (1% final concentration DMSO in all wells). Following a 72 hour incubation, biomass was quantified using the Sulforhodamine B (SRB) assay, and IC50 values (in µM) were calculated from logistical dose response curves. Averages were obtained from three independent experiments, and error is standard error (n=3).